{"id":391844,"date":"2020-12-02T09:18:10","date_gmt":"2020-12-02T14:18:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391844"},"modified":"2020-12-02T09:18:10","modified_gmt":"2020-12-02T14:18:10","slug":"pharmacyte-biotech-successfully-completes-9-month-stability-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/","title":{"rendered":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>PharmaCyte Biotech Successfully Completes 9-Month Stability Study<\/b><\/p>\n<p>LAGUNA HILLS, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box<sup>\u00ae<\/sup>, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps\u2122 final product, which will be used in the company\u2019s planned clinical trial in locally advanced, inoperable pancreatic cancer.\n<\/p>\n<p>\nPharmaCyte\u2019s Chief Executive Officer, Kenneth L. Waggoner, said of the completed nine-month stability study, \u201cThe product stability studies of our CypCaps\u2122 product initiated prior to submitting our Investigational New Drug application (IND) to the FDA are still proceeding smoothly while we are answering the questions raised by the FDA following our IND submission. We are also starting additional studies designed to provide information that the FDA has requested, which are mainly focused on the handling of the CypCaps\u2122 product in the clinic, and on additional animal data to add to the data that we have already supplied in our IND package.\n<\/p>\n<p>\n\u201cThe ongoing stability study is designed to determine the shelf life of the Cell-in-a-Box<sup>\u00ae<\/sup> encapsulated cell product, CypCaps\u2122, frozen at -80\u00b0C, and I am pleased to report that the nine-month time point was recently reached and that CypCaps\u2122 passed all of the necessary tests, including cell viability, enzyme activity and cell potency, pH, label check, capsule appearance and integrity. This nine-month data, as well as all future longer-term time points of the shelf life analyses, such as the next milestone, the 12-month time point, will be reported to the FDA as an update to our submitted IND.\u201d\n<\/p>\n<p>\nTo learn more about PharmaCyte\u2019s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company\u2019s documentary video complete with medical animations at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.PharmaCyte.com%2FCancer&amp;esheet=52341055&amp;newsitemid=20201202005348&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.PharmaCyte.com%2FCancer&amp;index=1&amp;md5=3420f20676c36a075febf6cc27cc7dd1\">https:\/\/www.PharmaCyte.com\/Cancer<\/a>.\n<\/p>\n<p><b>About PharmaCyte Biotech<\/b><\/p>\n<p>\nPharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \u201cCell-in-a-Box<sup>\u00ae<\/sup>.\u201d This technology is being used as a platform upon which therapies for several types of cancer and diabetes are being developed.\n<\/p>\n<p>\nPharmaCyte\u2019s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or \u201ccancer-killing\u201d form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient\u2019s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a \u201cbio-artificial liver\u201d and activate the chemotherapy drug at the site of the cancer. This \u201ctargeted chemotherapy\u201d has proven effective and safe to use in past clinical trials and we believe results in little to no treatment related side effects.\n<\/p>\n<p>\nPharmaCyte\u2019s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human liver cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also considering the use of genetically modified stem cells to treat diabetes. The encapsulation of the cell lines will be done using the Cell-in-a-Box<sup>\u00ae<\/sup> technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a \u201cbio-artificial pancreas\u201d for purposes of insulin production.\n<\/p>\n<p><b>Safe Harbor<\/b><\/p>\n<p>\nThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to raise the necessary capital to fund our operations and to find partners to supplement our capabilities and resources, our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.\n<\/p>\n<p>\nMore information about PharmaCyte Biotech can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.PharmaCyte.com&amp;esheet=52341055&amp;newsitemid=20201202005348&amp;lan=en-US&amp;anchor=www.PharmaCyte.com&amp;index=2&amp;md5=98b73055a1a3e8ace59e2a8735d9550c\">www.PharmaCyte.com<\/a>. Information may also be obtained by contacting PharmaCyte\u2019s Investor Relations Department.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201202005348\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201202005348\/en\/<\/a><\/span><\/p>\n<p><b>Dr. Gerald W. Crabtree<br \/>\n<\/b><br \/><b>Investor Relations:<br \/>\n<\/b><br \/>PharmaCyte Biotech, Inc.<br \/>\n<br \/>Investor Relations Department<br \/>\n<br \/>Telephone: 917.595.2856<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:Info@PharmaCyte.com\">Info@PharmaCyte.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> FDA Diabetes Clinical Trials Stem Cells Other Health Biotechnology General Health Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201202005348\/en\/610543\/3\/PMCB_logoC100p.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>PharmaCyte Biotech Successfully Completes 9-Month Stability Study LAGUNA HILLS, Calif.&#8211;(BUSINESS WIRE)&#8211; PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box\u00ae, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps\u2122 final product, which will be used in the company\u2019s planned clinical trial in locally advanced, inoperable pancreatic cancer. PharmaCyte\u2019s Chief Executive Officer, Kenneth L. Waggoner, said of the completed nine-month stability study, \u201cThe product stability studies of our CypCaps\u2122 product initiated prior to submitting our Investigational New Drug application (IND) to the FDA are still proceeding smoothly while we &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PharmaCyte Biotech Successfully Completes 9-Month Stability Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391844","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PharmaCyte Biotech Successfully Completes 9-Month Stability Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmaCyte Biotech Successfully Completes 9-Month Stability Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PharmaCyte Biotech Successfully Completes 9-Month Stability Study LAGUNA HILLS, Calif.&#8211;(BUSINESS WIRE)&#8211; PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box\u00ae, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps\u2122 final product, which will be used in the company\u2019s planned clinical trial in locally advanced, inoperable pancreatic cancer. PharmaCyte\u2019s Chief Executive Officer, Kenneth L. Waggoner, said of the completed nine-month stability study, \u201cThe product stability studies of our CypCaps\u2122 product initiated prior to submitting our Investigational New Drug application (IND) to the FDA are still proceeding smoothly while we &hellip; Continue reading &quot;PharmaCyte Biotech Successfully Completes 9-Month Stability Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T14:18:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PharmaCyte Biotech Successfully Completes 9-Month Stability Study\",\"datePublished\":\"2020-12-02T14:18:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/\"},\"wordCount\":886,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/\",\"name\":\"PharmaCyte Biotech Successfully Completes 9-Month Stability Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-02T14:18:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmacyte-biotech-successfully-completes-9-month-stability-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmaCyte Biotech Successfully Completes 9-Month Stability Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/","og_locale":"en_US","og_type":"article","og_title":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study - Market Newsdesk","og_description":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study LAGUNA HILLS, Calif.&#8211;(BUSINESS WIRE)&#8211; PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box\u00ae, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps\u2122 final product, which will be used in the company\u2019s planned clinical trial in locally advanced, inoperable pancreatic cancer. PharmaCyte\u2019s Chief Executive Officer, Kenneth L. Waggoner, said of the completed nine-month stability study, \u201cThe product stability studies of our CypCaps\u2122 product initiated prior to submitting our Investigational New Drug application (IND) to the FDA are still proceeding smoothly while we &hellip; Continue reading \"PharmaCyte Biotech Successfully Completes 9-Month Stability Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T14:18:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study","datePublished":"2020-12-02T14:18:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/"},"wordCount":886,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/","name":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-02T14:18:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005348r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmacyte-biotech-successfully-completes-9-month-stability-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391844"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391844\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}